MEMBRANE: Preventing Recurrences of Chronic Subdural Hematoma in Adult Patients by Middle Meningeal Artery Embolization

Sponsor
Unfallkrankenhaus Berlin (Other)
Overall Status
Recruiting
CT.gov ID
NCT05327933
Collaborator
(none)
154
1
2
28.2
5.5

Study Details

Study Description

Brief Summary

Patients with a chronic subdural hematoma (cSDH), that is, a blood accumulation between two meninges developing over a long period of time, often have recurrent bleedings after an initial operation. The study aims to show that additional surgery reduces the risk of recurrent bleeding.

The additional procedure aims to block small blood vessels in the skull with tiny plastic particles. The small blood vessels are embolized using X-rays and a contrast medium and a fine tube that is inserted into the diseased vessels of the head via the groin.

Patients of full age who have undergone burr hole trepanation as a first operation, i.e. a blood drain through a hole in the cranial cavity, can participate in the study. Participating patients are randomly assigned to a control group with treatment according to clinical routine or a treatment group with an additional occlusion of the blood vessels in the skull. In addition, patients can consent to a genetic test to determine the relationship between a coagulation factor and the risk of recurrence of the hematoma. In order to record the test results, check-up examinations are carried out after one and three months.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Surgery plus endovascular MMA embolization
  • Procedure: Surgery alone
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
154 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Middle Meningeal Artery Embolization Minimizes Burdensome Recurrence Rates After Newly Diagnosed Chronic Subdural Hematoma Evacuation (MEMBRANE)
Actual Study Start Date :
May 26, 2022
Anticipated Primary Completion Date :
Oct 1, 2024
Anticipated Study Completion Date :
Oct 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Surgery plus endovascular MMA embolization

Procedure: Surgery plus endovascular MMA embolization
A micro catheter is inserted transfemorally into the branches of the middle meningeal artery (MMA) in a minimally invasive manner and the periphery is occluded using polyvinyl alcohol (PVA) particles to prevent future bleeding. If the desired catheter position cannot be achieved due to the anatomical conditions, a more proximal closure of the MMA using Onyx® or micro-electric coils is performed. Embolization of the MMA by PVA particles with sizes between 40-300 µm is preferred over embolization by coils and Onyx®, since the capillary network of the dura is entirely blocked when using particles. In order to identify the vessels to be closed, a digital subtraction angiography (DSA) is performed.

Active Comparator: Surgery alone

Procedure: Surgery alone
Evacuation of cSDH

Outcome Measures

Primary Outcome Measures

  1. cSDH recurrence rates after surgery [Within three months of follow-up]

    A recurrence occurs when at least one of the following criteria is met: recurrent cSDH with at least the same volume (>- 10%) compared to the findings at baseline and / or recurrent cSDH which requires surgery

Secondary Outcome Measures

  1. Impairment due to neurological deficits assessed by the modified Rankin Scale [Evaluated at three months after baseline]

    Modified Rankin scale ranges from 0 (no symptoms) to 5 (severe disability)

  2. Number of recurrence-associated complications [Within three months of follow-up]

    Examined on a binary scale

  3. Number of complications associated with interventional therapy [Within three months of follow-up]

    Examined on a binary scale

Other Outcome Measures

  1. Relationship between factor XIII deficiency and risk of recurrence [Within three months of follow-up]

    Factor XIII deficiency is defined if the factor XIII concentration at baseline and/or the factor XIII activity after cryopreservation is <70%.

  2. Predisposition of the genetic variants F13A1 rs2815822 and F13B rs12134960 for factor XIII deficiency [Within three months of follow-up]

    The existence of genetic variants F13A1 rs2815822 or F13B rs12134960 in the blood of the subjects is determined on a binary scale.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Patients who have undergone surgery by means of one or more burr hole trepanations during the first manifestation of a cSDH (unihemispherical or bihemispherical) detected by computed tomography or magnetic resonance tomography

  2. Age ≥18 years

  3. Sufficient compliance and ability to consent

  4. Patient's informed consent for surgical as well as endovascular interventional procedure and participation in the study

Exclusion Criteria:
  1. Conservatively treated cSDH

  2. Radiological evidence of an acute or subacute subdural hematoma, subarachnoid hemorrhage, intracerebral hematoma or epidural hematoma

  3. Surgical technique: craniotomy, craniectomy, bilateral burr hole trepanation

  4. Angiography cannot be performed within 72 hours after surgery

  5. Age <18 years

  6. Supervisory relationship

  7. Pregnancy

  8. Lack of informed consent

  9. Lack of compliance

  10. Homozygous factor XIII deficiency with residual activity <10%

Contacts and Locations

Locations

Site City State Country Postal Code
1 Unfallkrankenhaus Berlin Berlin Germany 12683

Sponsors and Collaborators

  • Unfallkrankenhaus Berlin

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Johannes Lemcke, Deputy Head Department of Neurosurgery, Unfallkrankenhaus Berlin
ClinicalTrials.gov Identifier:
NCT05327933
Other Study ID Numbers:
  • MMA_SP
  • DRKS00020465
First Posted:
Apr 14, 2022
Last Update Posted:
May 31, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 31, 2022